The right to be forgotten reduces financial toxicity in cancer survivors
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
Precision oncology is the goal today, not a simple slogan
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
Cancer Research
Good night for good? Preventing sleeping cancer cells from awakening
Metastases are the main cause of cancer-related deaths. Preventing hibernating cancer cells from awakening therefore represents an urgent, unmet medical need.
Cancer Research
Conquering cancer: an attainable goal?
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
Predict the next evolutionary move of cancer: a feasible winning strategy?
Tumour evolution is one of the primary reasons for resistance to treatment and researchers are now learning how to use it to lead tumours down a dead end
Momentous achievements in oncology treatment: where will the wave of innovation take cancer care?
Efficacy of targeted therapies has enabled unprecedented survival gains in the last few years, but Prof. Jean-Charles Soria believes overcoming drug resistance is likely to be a local battle fought in the tumour microenvironment
CAR-T cell therapy in solid tumours: will we ever replicate the success rates achieved in blood cancers?
Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl
Artificial intelligence: a game-changer for the future of cancer care
Faced with an explosion in the complexity of genomic, imaging and clinical data, AI is rapidly becoming an indispensable tool for oncologists.
Breast cancer treatment should be tailored to the tumour biology – not to its hormone-receptor status alone
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi
HER2+ breast cancer: from no hope to good prognosis in 20 years
Trastuzumab has transformed the prognosis for women with HER2+ breast cancer. On the occasion of the ESMO Breast Cancer Virtual Congress 2021, leading oncology experts recall with enthusiasm the pioneering work of researchers like José Baselga in this field and push for continuous research to investigate how to further improve the treatment of this cancer sub-type